Yep, wenn man sich anschaut, was Gilead allein beim Erstinvestment vor 9 Jahren in Galapagos investiert hat, dann würde beim derzeitigen Aktienkurs von Gala eine Übernahme sinnvoll erscheinen, wenn sie denn wissenschaftlich vertretbar ist.
2015 Gilead;
https://www.gilead.com/news/news-details/2015/...nflammatory-diseases
"Galapagos will receive an upfront license fee of $300 million and Gilead will make a $425 million equity investment in Galapagos by subscribing for shares at a price of €58 per share, which represents a 20% premium as compared to the average share price over the last 30 days.
After the issuance of the shares, Gilead will own approximately 15% of the outstanding share capital of Galapagos depending on the $/€ exchange rate at closing. Galapagos is eligible to receive further development, regulatory and commercial milestone payments up to $1.35 billion, plus tiered royalties on global sales starting at 20%, with the exception of the co-promotion territories where profits will be shared equally."
Galapagos-Chart seit Gilead-Invest |
